All-oral Hep C race heats up as AbbVie receives "breakthrough" status

Share this article:

AbbVie joined BMS today in gaining Breakthrough Therapy designation for an investigational Hep C treatment. The three drug combo of ABT-450/r (protease inhibitor and ritonavir), ABT-267 (an NS5A inhibitor) and ABT-333 (a non-nucleoside polymerase inhibitor) treats patients with genotype 1 of the chronic disease.

FDA's Breakthrough Therapy nod follows a promising Phase II clinical trial, named ‘Aviator'. In that trial, the three-drug combo saw 99% of patients hit the key benchmark of sustained viral response after 12 weeks of therapy. The combo will now move to Phase III trials.

John Leonard, SVP and Chief Scientific Officer, AbbVie, said in a release: "AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. We feel it reflects the potential of this regimen to be important in the treatment of HCV."

Five days ago, Gilead released data from its Phase II "Lonestar" study, in which the company tested a combination of sofosbuvir, which has been submitted for FDA approval, and ledipasvir. The Foster-City, California based drugmaker said the virus was undetectable in 19 out of 20 subjects after only eight weeks.

Share this article:

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.